Neovacs obtains FDA “Fast Track” designation for IFNα Kinoid in Lupus (SLE)
December 07, 2016 02:15 ET
|
Neovacs, Inc.
PARIS and BOSTON, Dec. 07, 2016 (GLOBE NEWSWIRE) -- Neovacs (Alternext Paris:ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced that the U.S. Food...
Neovacs signs production partnership with 3P Biopharmaceuticals, a leading GMP producer of biological drugs
November 23, 2016 12:00 ET
|
Neovacs, Inc.
Agreement addresses future production needs of IFNα, key component of IFN Kinoid1 PARIS and BOSTON, Nov. 23, 2016 (GLOBE NEWSWIRE) -- Neovacs (Alternext Paris:ALNEV), a leader in active...
Neovacs Acquires Interferon Alpha Manufacturing Technology From AMEGABIOTECH
November 15, 2016 02:15 ET
|
Neovacs, Inc.
PARIS and BOSTON, Nov. 15, 2016 (GLOBE NEWSWIRE) -- Neovacs (Alternext Paris:ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced an agreement with...
Neovacs enrolls the first U.S. Patient in Phase IIb study of IFNa Kinoid for treatment of Systemic Lupus Erythematosus (SLE)
November 07, 2016 02:15 ET
|
Neovacs, Inc.
PARIS and BOSTON, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Neovacs (Alternext Paris:ALNEV) (PEA-eligible SMEs), a leader in active immunotherapy for the treatment of autoimmune diseases, today announced...
Neovacs to attend Jefferies 2016 London Healthcare Conference November 16 & 17, 2016
November 03, 2016 02:30 ET
|
Neovacs, Inc.
PARIS and BOSTON, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Neovacs (Alternext Paris:ALNEV) a leader in active immunotherapy for the treatment of autoimmune diseases, today announced its participation at...
Neovacs Signs a Cooperation Agreement With the Department Immunology of Diabetes at the Reputed Hospital Cochin in Paris
October 12, 2016 10:18 ET
|
Neovacs, Inc.
PARIS, Oct. 12, 2016 (GLOBE NEWSWIRE) -- NEOVACS (Alternext Paris:ALNEV) (PEA-PME eligible), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced a...
Half-Year Results 2016 and Update on Operational Development
September 30, 2016 13:45 ET
|
Neovacs, Inc.
Cash position significantly strengthened by successful capital increasePhase IIb clinical trial in lupus expanded into the United States PARIS, Sept. 30, 2016 (GLOBE NEWSWIRE) -- NEOVACS (Alternext...
Neovacs to present at two major Investor Conferences:
August 30, 2016 02:15 ET
|
Neovacs, Inc.
PARIS and BOSTON, Aug. 30, 2016 (GLOBE NEWSWIRE) -- Neovacs (Alternext Paris:ALNEV), a leader in active immunotherapy for the treatment of autoimmune diseases, today announced CEO Miguel Sieler will...
Neovacs to attend ChinaBio® Event May 18 & 19, 2016
May 17, 2016 02:15 ET
|
Neovacs, Inc.
PARIS and BOSTON, May 17, 2016 (GLOBE NEWSWIRE) -- Neovacs (Alternext Paris:ALNEV) a leader in active immunotherapy for the treatment of autoimmune diseases, today announced its participation at the...
Neovacs obtains FDA approval to extend its Phase IIb clinical trial in Lupus to United States
April 28, 2016 11:40 ET
|
Neovacs, Inc.
PARIS and BOSTON, April 28, 2016 (GLOBE NEWSWIRE) -- Neovacs (Alternext Paris:ALNEV) a leader in active immunotherapy for the treatment of autoimmune diseases, today announced that the Company has...